



**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (EXCEPT TO “QUALIFIED INSTITUTIONAL BUYERS” AS DEFINED IN RULE 144A UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)), AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT IS NOT A PROSPECTUS AND NOT AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION, INCLUDING, WITHOUT LIMITATION, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR THE PEOPLE'S REPUBLIC OF CHINA.**

#### Media release

### **Lepu Medical Technology (Beijing) Co., Ltd. launches offering of global depository receipts to be listed on SIX Swiss Exchange**

- Lepu Medical Technology (Beijing) Co., Ltd., the only total-solution provider in the PRC across the full life cycle of cardiovascular disease management, today announces the launch of its offering of global depository receipts to be listed on SIX Swiss Exchange.
- The Offering consists of up to 11,910,286 Firm GDRs, and up to an additional 5,774,110 GDRs pursuant to an upsize option. Each GDR represents five newly issued A Shares of the Company with a fully paid nominal value of RMB 1.00 each.
- The Offering is expected to raise approximately USD 148.8 million, assuming all Firm GDRs are sold (and no exercise of the Upsize Option) at the mid-point of the Offer Price Range of USD 12.31 to USD 12.68. Assuming the sale of all GDRs at an offer price that is at the mid-point of the Offer Price Range with full exercise of the Upsize Option, the Offering is expected to raise approximately USD 221.0 million of gross proceeds.
- The offer period commences at 10:00 CEST today, September 15, 2022 and is expected to end at 17:00 CEST on September 15, 2022, subject to acceleration or extension of the timetable of the Offering.
- The proceeds from the Offering are intended for the Company's (i) implementation of global R&D initiatives and commercialization of products to better meet patients' needs globally, (ii) establishment of production sites overseas, (iii) establishment of business development centers overseas and seeking of product co-development opportunities, sales and marketing activities of products globally, and formation of strategic collaboration with sales, marketing, and distribution partners, (iv) building of sales and distribution network globally with customer service capabilities, as well as (v) to supplement the working capital for general corporate purposes.

**Zurich, Switzerland, September 15, 2022**– Lepu Medical Technology (Beijing) Co., Ltd. (the “**Company**” or “**Lepu Medical**”), the only total-solution provider in the PRC across the full life cycle of cardiovascular disease management, today announces the launch of its offering (the “**Offering**”) of global depository receipts (the “**GDRs**”) on SIX Swiss Exchange AG (the “**SIX Swiss Exchange**”).

The Offering is expected to take place from today, September 15, 2022 at 10:00 Central European Summer Time (“**CEST**”) to September 15, 2022 at 17:00 CEST, subject to acceleration or extension of the timetable of the Offering. The determination of the final number of GDRs and the final Offer Price is expected to take place on or around September 15, 2022, with trading expected to commence on or around September 21, 2022.

Credit Suisse AG (“**Credit Suisse**”), CLSA Limited (“**CLSA**”) and China International Capital Corporation (UK) Limited (“**CICC**”) are acting as Joint Global Coordinators in the Offering. Credit Suisse, CLSA, CICC, China Galaxy International Securities (Hong Kong) Co., Limited, Huatai Financial Holdings (Hong Kong) Limited and Haitong International Securities Company Limited are acting as Joint Bookrunners in the Offering.

**Not for release, publication or distribution in whole or in part in or into the United States (except to qualified institutional buyers as defined in Rule 144A under the Securities Act), Canada, Australia, Japan, South Africa or any other jurisdiction in which the distribution or release would be unlawful.**

---

### **About Lepu Medical**

The Company is the only total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions according to Frost & Sullivan. It is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated its first-mover advantage through relentless innovation since its inception in 1999. The Company's key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon, all ranked top three in the PRC, according to the same source, in terms of operating revenue in 2021. The Company has grown steadily for the past 15 consecutive years at a CAGR of 31.5% in operating revenue and a CAGR of 24.9% in net profit. It has been listed on the Shenzhen Stock Exchange (SZSE: 300003.SZ) since October 2009.

The Company organizes its business into three operating segments:

- **Medical Devices.** The Company primarily offers cardiovascular medical devices such as coronary interventional products, structural heart disease products, cardiac rhythm management products, digital subtraction angiography equipment, and peripheral interventional products. The Company is a pioneer in the innovative coronary medical device market in the PRC. Leveraging its technical capabilities and industry expertise, as well as sales and supply chain networks from the cardiovascular market, the Company has further expanded into in vitro diagnostics equipment and test kits, and surgical & anesthetic devices and consumables. As of June 30, 2022, it had obtained 541 NMPA type II and type III licenses, 234 CE certificates and 34 FDA approvals in medical devices.
- **Pharmaceuticals.** The Company offers both active pharmaceutical ingredient and finished dosage forms (FDF) pharmaceuticals. It provides one of the most comprehensive cardiovascular FDF offerings in the PRC. As of June 30, 2022, it had 87 pharmaceuticals included in the National Reimbursement Drug List including primarily antihyperlipidemic, antihypertensive, antihyperglycemic, anti-thrombotic, and anti-heart failure pharmaceuticals.
- **Medical Care Solutions.** The Company offers cardiovascular-related medical care solutions through its cardiovascular hospital, Internet hospitals, check-up center, independent clinical laboratories, and online pharmacies. It also provides solutions to facilitate cardiovascular patients' health management at home.

### **About the Offering**

The Offering consists of up to 11,910,286 GDRs (the "**Firm GDRs**"), and up to an additional 5,774,110 GDRs pursuant to an upsize option (the "**Upsize GDRs**"). Each GDR represents five newly issued A Shares of the Company with a fully paid nominal value of RMB 1.00 each. The Company's A Shares are listed on the Shenzhen Stock Exchange, while the listing of the GDRs will be on SIX Swiss Exchange, in accordance with the Standard for Depository Receipts.

The upsize option contained in the Offering (the "**Upsize Option**") may be jointly exercised by the Company and the Joint Global Coordinators (on behalf of the Joint Global Coordinators and Joint Bookrunners), on the date of pricing of the Offering, where the number of GDRs sold in connection with this Upsize Option will depend on investor demand.

The Company expects the offer price per GDR (the "**Offer Price**") to be set within the offer price range of USD 12.31 to USD 12.68 (the "**Offer Price Range**"). The Offer Price will be determined among the Company and the Joint Global Coordinator following a bookbuilding process. The Company expects to publish the final Offer Price and the final number of GDRs sold in the Offering on or around September 15, 2022.

The Offering is expected to raise approximately USD 148.8 million of gross proceeds assuming the sale of all Firm GDRs at an offer price that is at the mid-point of the Offer Price Range, and no exercise of the Upsize Option. Assuming the sale of all GDRs at an offer price that is at the mid-point of the Offer Price Range with full exercise of the Upsize Option, the Offering is expected to raise approximately USD 221.0 million of gross proceeds. The Company's net proceeds would be obtained after deducting the total fees, costs, and expenses connected with the Offering (inclusive of value added taxes).

Of the net proceeds raised from the Offering, the Company intends to use (i) approximately 40% for the implementation of global research and development ("**R&D**") initiatives and commercialize products to better meet patients' needs globally, (ii) approximately 20% for the establishment of production sites overseas, (iii)

**Not for release, publication or distribution in whole or in part in or into the United States (except to qualified institutional buyers as defined in Rule 144A under the Securities Act), Canada, Australia, Japan, South Africa or any other jurisdiction in which the distribution or release would be unlawful.**

approximately 10% to establish business development centers overseas and seek opportunities to co-develop products empowered by leading technologies, conduct sales and marketing activities of products globally, and form strategic collaboration with sales, marketing, and distribution partners, (iv) approximately 10% to build sales and distribution network globally with customer service capabilities to broaden sale channels and increase penetration into more medical and retail institutions to enhance brand awareness globally, and (v) the remaining 20% to supplement the working capital for general corporate purposes.

The Offering consists of (i) a private placement in Switzerland solely to professional clients within the meaning of art. 4 para. 3 of the Swiss Federal Act on Financial Services (the “**FinSA**”); (ii) an offering in the United States of America (“**United States**” or “**US**”) only to “qualified institutional buyers” as defined in, and in reliance upon, Rule 144A (“**Rule 144A**”), or another exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933, as amended (the “**Securities Act**”); and (iii) private placements in certain jurisdictions outside of Switzerland and the United States in accordance with applicable securities laws and on the basis of various exemptions, including those provided by the Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”) and/or Regulation (EU) 2017/1129 as it forms part of domestic UK law by virtue of the European Union (Withdrawal) Act 2018 (“**UK Prospectus Regulation**”). All offers and sales outside the United States will be made in compliance with Regulation S under the Securities Act.

#### **Offering data and timetable**

Listing venue	SIX Swiss Exchange
Ticker symbol	LEPU
Swiss Security Number-144A/Reg S	121526184 / 121526183
GDR ISIN-144A/Reg S	US52678P1066 / US52678P2056
<b>Indicative dates of principal events of the Offering</b>	
Start of offer period	September 15, 2022
End of offering period	September 15, 2022 (at 17:00 CEST)
Determination of final Offer Price and final number of GDRs sold	September 15, 2022
Publication of final Offer Price and final number of GDRs sold	September 15, 2022
First Day of Trading	September 21, 2022 (at 15:00 CEST)
Payment and Settlement	September 21, 2022

#### **Contact information**

Phone: +86 010 80120622, E-mail: [zqb@lepumedical.com](mailto:zqb@lepumedical.com)

#### **Media inquiries**

For media inquiries, please contact the Company at [marketing@lepu-medical.com](mailto:marketing@lepu-medical.com).

#### **Important information**

This announcement may not be published, distributed or transmitted, directly or indirectly, in the United States of America (including its territories and possessions) (except to “qualified institutional buyers” as defined in Rule 144A under the Securities Act (“QIBs”)), Australia, Canada, Japan or any other jurisdiction where such announcement could be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons who are in possession of this document or other information referred to herein should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement does not constitute an offer of, or a solicitation of an offer to purchase, securities of the Company or of any of its subsidiaries in the United States of America or any other jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, an offer in any jurisdiction.

The GDRs offered have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States, except to QIBs pursuant to Rule 144A under the Securities Act or another exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable state or local securities law. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from

**Not for release, publication or distribution in whole or in part in or into the United States (except to qualified institutional buyers as defined in Rule 144A under the Securities Act), Canada, Australia, Japan, South Africa or any other jurisdiction in which the distribution or release would be unlawful.**

---

the Company and that will contain detailed information about the Company and management, as well as financial statements.

This announcement does not constitute an offer to sell or a solicitation to buy securities of the Company and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. The offer and listing will be made solely by means of, and based on, a prospectus which has been approved by the competent review body and published. An investment decision regarding the securities referred to herein should be based exclusively on the prospectus. The prospectus is available free of charge for 12 months following the First Day of Trading on SIX Swiss Exchange from Lepu Medical Technology (Beijing) Co., Ltd., No. 37 Chaoqian Road, Changping District, Beijing, the PRC (phone: +86 010- 8012 0666; Email: marketing@lepu-medical.com).

In member states of the European Economic Area (the "EEA") the placement of securities described in this announcement is directed exclusively at persons who are "qualified investors" within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation").

This announcement does not constitute an "offer of securities to the public" within the meaning of the Prospectus Regulation of the Securities in any member state of the EEA or the Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (the "UK Prospectus Regulation"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Regulation, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.

In the United Kingdom, this document is for distribution only to, and directed only at, persons who are "qualified investors" within the meaning of Article 2(e) of the UK Prospectus Regulation and who (i) have professional experience in matters relating to investments (being investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order")), (ii) are persons falling within article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Financial Promotion Order, or (iii) are otherwise persons to whom it may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). In the United Kingdom, this document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons.

This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors and other persons who are permitted to subscribe for the securities described herein pursuant to an exemption from the Prospectus Regulation and other applicable legislation and will only be engaged in with such persons.

In Switzerland, the securities described in this announcement will be offered solely to professional clients within the meaning of article 4 para 3 of FinSA. The securities may not be publicly offered, directly or indirectly, in Switzerland within the meaning of FinSA. Each purchaser of the securities in Switzerland will be deemed to have represented and agreed that it qualifies as a "professional client" within the meaning of the FinSA.

The securities are not being offered or sold and may not be offered or sold, directly or indirectly, in the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan), except as permitted by the applicable laws of the People's Republic of China, including the PRC Securities Law.

No action has been taken that would permit an offering or an acquisition of the securities or a distribution of this announcement in any jurisdiction where such action would be unlawful. Persons into whose possession this announcement comes are required to inform themselves about and to observe any such restrictions.

This announcement does not constitute a recommendation concerning the placement. Investors should consult a professional advisor as to the suitability of the placement for the person concerned.

This announcement may contain forward looking statements, estimates, opinions, and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified using forward-looking terminology, including the terms "believes," "estimates,"

**Not for release, publication or distribution in whole or in part in or into the United States (except to qualified institutional buyers as defined in Rule 144A under the Securities Act), Canada, Australia, Japan, South Africa or any other jurisdiction in which the distribution or release would be unlawful.**

---

"anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations, and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release. Lepu Medical undertakes no obligation, and does not expect to publicly update, or publicly revise, any of the information, forward-looking statements or the conclusions contained herein or to reflect new events or circumstances or to correct any inaccuracies which may become apparent subsequent to the date hereof, whether as a result of new information, future events or otherwise. Lepu Medical accepts no liability whatsoever in respect of the achievement of such forward-looking statements and assumptions.

None of the Joint Global Coordinators or the Joint Bookrunners (together, the "Managers") or any of their respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents, alliance partners or any other entity or person accepts any responsibility or liability whatsoever for, or makes any representation, warranty or undertaking, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Group, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith. Accordingly, each of the Managers and the other foregoing persons disclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract or that they might otherwise be found to have in respect of this announcement and/or any such statement.